PL3495352T3 - Postacie krystaliczne antagonisty receptora androgenowego, ich sposób wytwarzania i zastosowanie - Google Patents
Postacie krystaliczne antagonisty receptora androgenowego, ich sposób wytwarzania i zastosowanieInfo
- Publication number
- PL3495352T3 PL3495352T3 PL17842980T PL17842980T PL3495352T3 PL 3495352 T3 PL3495352 T3 PL 3495352T3 PL 17842980 T PL17842980 T PL 17842980T PL 17842980 T PL17842980 T PL 17842980T PL 3495352 T3 PL3495352 T3 PL 3495352T3
- Authority
- PL
- Poland
- Prior art keywords
- preparation
- receptor antagonist
- androgen receptor
- crystal forms
- crystal
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610737732 | 2016-08-26 | ||
| CN201610871736 | 2016-09-30 | ||
| CN201610876685 | 2016-10-08 | ||
| EP17842980.9A EP3495352B1 (en) | 2016-08-26 | 2017-08-25 | Crystal forms of an androgen receptor antagonist, preparation method and use thereof |
| PCT/CN2017/099036 WO2018036558A1 (zh) | 2016-08-26 | 2017-08-25 | 一种雄激素受体拮抗剂药物的晶型及其制备方法和用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3495352T3 true PL3495352T3 (pl) | 2021-08-02 |
Family
ID=61246439
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17842980T PL3495352T3 (pl) | 2016-08-26 | 2017-08-25 | Postacie krystaliczne antagonisty receptora androgenowego, ich sposób wytwarzania i zastosowanie |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US10815221B2 (pl) |
| EP (1) | EP3495352B1 (pl) |
| JP (1) | JP6716023B2 (pl) |
| CN (1) | CN109641851B (pl) |
| CY (1) | CY1124083T1 (pl) |
| DK (1) | DK3495352T3 (pl) |
| ES (1) | ES2869882T3 (pl) |
| HR (1) | HRP20210667T1 (pl) |
| HU (1) | HUE053958T2 (pl) |
| LT (1) | LT3495352T (pl) |
| PL (1) | PL3495352T3 (pl) |
| PT (1) | PT3495352T (pl) |
| RS (1) | RS61773B1 (pl) |
| SI (1) | SI3495352T1 (pl) |
| WO (1) | WO2018036558A1 (pl) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018162793A1 (en) * | 2017-03-07 | 2018-09-13 | Orion Corporation | Manufacture of a crystalline pharmaceutical product |
| WO2019028689A1 (zh) * | 2017-08-09 | 2019-02-14 | 杭州领业医药科技有限公司 | Odm-201晶型及其制备方法和药物组合物 |
| EP3759076A1 (en) * | 2018-02-27 | 2021-01-06 | Sandoz AG | Crystalline form ii of darolutamide |
| KR20210093900A (ko) * | 2018-10-18 | 2021-07-28 | 젬파이어 세러퓨틱스 인코포레이티드 | 젬카빈, 이의 약학적으로 허용가능한 염, 이의 조성물 및 이의 사용 방법 |
| WO2022036782A1 (zh) * | 2020-08-18 | 2022-02-24 | 拜耳消费者护理股份有限公司 | 一种雄激素受体拮抗剂药物的晶型csvi及其制备方法和用途 |
| WO2023161458A1 (en) | 2022-02-28 | 2023-08-31 | Química Sintética, S.A. | Crystalline form of darolutamide |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR078793A1 (es) * | 2009-10-27 | 2011-12-07 | Orion Corp | Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros |
| BR112013026905B1 (pt) * | 2011-04-21 | 2021-09-14 | Orion Corporation | Compostos de carboxamida moduladora do receptor de andrógeno e seu uso no tratamento e prevenção de câncer de próstata, bem como composições farmacêuticas compreendendo os ditos compostos |
| EP3250554B1 (en) * | 2015-01-30 | 2022-05-18 | Orion Corporation | A carboxamide derivative and its diastereomers in stable crystalline form |
| WO2019028689A1 (zh) | 2017-08-09 | 2019-02-14 | 杭州领业医药科技有限公司 | Odm-201晶型及其制备方法和药物组合物 |
-
2017
- 2017-08-25 JP JP2019511530A patent/JP6716023B2/ja active Active
- 2017-08-25 WO PCT/CN2017/099036 patent/WO2018036558A1/zh unknown
- 2017-08-25 PL PL17842980T patent/PL3495352T3/pl unknown
- 2017-08-25 CN CN201780048143.1A patent/CN109641851B/zh active Active
- 2017-08-25 EP EP17842980.9A patent/EP3495352B1/en active Active
- 2017-08-25 LT LTEP17842980.9T patent/LT3495352T/lt unknown
- 2017-08-25 RS RS20210521A patent/RS61773B1/sr unknown
- 2017-08-25 HU HUE17842980A patent/HUE053958T2/hu unknown
- 2017-08-25 PT PT178429809T patent/PT3495352T/pt unknown
- 2017-08-25 US US16/328,249 patent/US10815221B2/en active Active
- 2017-08-25 ES ES17842980T patent/ES2869882T3/es active Active
- 2017-08-25 DK DK17842980.9T patent/DK3495352T3/da active
- 2017-08-25 SI SI201730734T patent/SI3495352T1/sl unknown
-
2021
- 2021-04-27 CY CY20211100367T patent/CY1124083T1/el unknown
- 2021-04-27 HR HRP20210667TT patent/HRP20210667T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RS61773B1 (sr) | 2021-05-31 |
| CN109641851B (zh) | 2022-09-02 |
| CN109641851A (zh) | 2019-04-16 |
| WO2018036558A1 (zh) | 2018-03-01 |
| PT3495352T (pt) | 2021-05-03 |
| HRP20210667T1 (hr) | 2021-05-28 |
| JP2019526570A (ja) | 2019-09-19 |
| EP3495352B1 (en) | 2021-01-27 |
| US10815221B2 (en) | 2020-10-27 |
| ES2869882T3 (es) | 2021-10-26 |
| US20200239450A1 (en) | 2020-07-30 |
| SI3495352T1 (sl) | 2021-08-31 |
| DK3495352T3 (da) | 2021-05-03 |
| CY1124083T1 (el) | 2022-03-24 |
| LT3495352T (lt) | 2021-06-10 |
| EP3495352A4 (en) | 2019-06-12 |
| HUE053958T2 (hu) | 2021-08-30 |
| EP3495352A1 (en) | 2019-06-12 |
| JP6716023B2 (ja) | 2020-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1247204A1 (zh) | 用於雄激素受體的靶向降解的化合物和方法 | |
| RS61773B1 (sr) | Kristalni oblici antagonista androgenog receptora, postupak njihove pripreme i upotrebe | |
| HK1250710A1 (zh) | 用於製備雄激素受體拮抗劑及其中間體的方法 | |
| EP3094346A4 (en) | Vista antagonist and methods of use | |
| IL284005A (en) | Glucocorticoid receptor inhibitors | |
| EP3313396A4 (en) | G-PROTEIN-COUPLED RECEPTOR CINASE INHIBITORS AND METHOD OF USE THEREOF | |
| HUE055891T2 (hu) | A gonadotropint felszabadító hormon (GNRH) receptor antagonista kristályos formája és annak elõállítási módja | |
| PL3216791T3 (pl) | Substancja polimorficzna chlorowodorku jonkenafilu, sposób jej wytwarzania oraz jej kompozycja i zastosowanie | |
| HK1250163A1 (zh) | 作為5-氧代-ete受體拮抗劑的吲哚類似物及其使用方法 | |
| IL284081A (en) | Somatostatin receptor antagonistic compounds and methods of using them | |
| RS60448B1 (sr) | Kristalni oblik inhibitora receptora androgena i postupak njegovog dobijanja | |
| EP3336088A4 (en) | CRYSTALLINE FORM OF THE OREXIN RECEPTOR ANTAGONIST COMPOUND, PREPARATION METHOD AND APPLICATION THEREOF | |
| GB201500638D0 (en) | Scaffold fitting means and method of use thereof | |
| EP3674294C0 (en) | N-FORMYL VORTIOXETINE, METHOD FOR PREPARING IT AND SOLID PREPARATION OF VORTIOXETINE |